Consistent with these findings, our study shows that NSDHL knockdown caused a significant reduction of total cholesterol level in breast cancer cells, accompanying the downregulation of EGFR and SREBP1, and has an additive or synergistic anti-cancer effect on erlotinib-treated breast cancer cells. Here, SREBF1 is linked to breast cancer.